Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

24.95
-1.3000-4.95%
Volume:231.80K
Turnover:5.80M
Market Cap:888.59M
PE:-26.55
High:26.00
Open:25.58
Low:24.21
Close:26.25
Loading ...

Harrow Launches Access and Affordability Program with Price Reductions for Branded Products

Business Wire
·
13 Nov 2024

Harrow Announces Market Access Wins for VEVYE®

Business Wire
·
12 Nov 2024

Harrow Partners with Asembia to Enhance Provider and Patient Experience Through Nationwide Digital Services and Hub Support for Harrow’s Branded Eyecare Products

Business Wire
·
07 Nov 2024

New Strong Buy Stocks for November 6th

Zacks
·
06 Nov 2024

Harrow To Report Third Quarter 2024 Financial Results After Market Close on November 13, 2024

Business Wire
·
31 Oct 2024

Best Momentum Stocks to Buy for October 24th

Zacks
·
24 Oct 2024

New Strong Buy Stocks for October 24th

Zacks
·
24 Oct 2024

3 US Growth Stocks With High Insider Ownership And 167% Earnings Growth

Simply Wall St.
·
18 Oct 2024

Rpt-Melt Pharmaceuticals - FDA Agrees to Melt-300 Phase 3 Special Protocol Assessment

THOMSON REUTERS
·
10 Oct 2024

Corrected- Melt Pharmaceuticals (Not 'Harrow Inc') - Topline Readout Expected in Q4 2024

THOMSON REUTERS
·
10 Oct 2024

Rpt-Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

THOMSON REUTERS
·
10 Oct 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, Melt-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

THOMSON REUTERS
·
10 Oct 2024

Harrow Inc - FDA Agrees to Melt-300 Phase 3 Special Protocol Assessment

THOMSON REUTERS
·
10 Oct 2024

Harrow Inc - Topline Readout Expected in Q4 2024

THOMSON REUTERS
·
10 Oct 2024

Melt Pharmaceuticals Announces Dosing of Last Patient in Pivotal Phase 3 Study of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Business Wire
·
10 Oct 2024

Harrow Is Maintained at Buy by Craig-Hallum

Dow Jones
·
04 Oct 2024